InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,996.89
(
0.33%
)
Post# of 3329
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

fsulevine

Send PM Follow Ignore
Followers 10
Posts 2086
Boards Moderated 0
Alias Born 05/15/2015

fsulevine

Re: Whalatane post# 3030

Thursday, 07/27/2017 4:18:04 PM

Thursday, July 27, 2017 4:18:04 PM

Post# of 3329
Okay, interesting. But am I confused here? I thought Auryxia is a phosphate binder... the iron improvement was a secondary benefit. So would that only hinder Auryxia sales for off-label prescriptions? And if someone taking it for use as a phosphate binder, then if they receive the secondary benefits, they would not need this other drug. If the patient simply has anemia and does not need a phosphate binder, then this drug would be more useful to them. I am far from an expert on kidney disease or how it is treated. Correct me if I am wrong.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up